<p>Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 獲取免費報告) 的股價在週二的午盤交易中達到了新的 52 周高點。該股最高交易價格為 36.13 美元，最後交易價格為 35.83 美元，成交量為 3,355,702 股。該股此前收盤價為 33.05 美元。</p>
<p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>多家股票研究分析師最近對 OLMA 股票發表了評論。瑞銀集團在 10 月 20 日的研究報告中重申了對 Olema Pharmaceuticals 股票的 “買入” 評級。高盛集團將 Olema Pharmaceuticals 的目標價格從 26.00 美元上調至 38.00 美元，並在 12 月 11 日的報告中給予該公司 “買入” 評級。HC Wainwright 將 Olema Pharmaceuticals 的目標價格從 36.00 美元上調至 45.00 美元，並在 12 月 11 日的報告中給予該股 “買入” 評級。古根海姆在 10 月 8 日的研究報告中開始覆蓋 Olema Pharmaceuticals。他們對該公司發佈了 “買入” 評級和 20.00 美元的價格目標。最後，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Olema Pharmaceuticals 股票的 “賣出（d-）” 評級。七位分析師對該股給予了買入評級，一位給予了持有評級，一位對該公司的股票發佈了賣出評級。根據 MarketBeat.com 的數據，該股的共識評級為 “適度買入”，共識目標價格為 40.50 美元。</p>
<p><strong>閲讀我們關於 OLMA 的最新報告</strong></p>
<h2>Olema Pharmaceuticals 股票表現</h2>
<p>該公司的債務與股本比率為 0.01，流動比率為 8.03，速動比率為 8.03。該公司的 50 日移動平均價格為 16.23 美元，200 日移動平均價格為 9.47 美元。該公司的市值為 24.6 億美元，市盈率為-19.16，貝塔值為 1.87。</p>
<p>Olema Pharmaceuticals (NASDAQ:OLMA - 獲取免費報告) 最近在 11 月 10 日發佈了季度財報。該公司報告每股收益（EPS）為-0.49 美元，低於分析師的共識預期-0.44 美元，差距為 0.05 美元。平均而言，股票研究分析師預測 Olema Pharmaceuticals, Inc.在本年度將發佈-2.33 的每股收益。</p>
<h2>內部活動</h2>
<p>在相關消息中，董事 Cyrus Harmon 在 9 月 18 日的交易中出售了 10,000 股該股票。該股票以平均價格 8.33 美元出售，總交易額為 83,300.00 美元。出售完成後，該董事直接持有 744,140 股公司股票，估值約為 6,198,686.20 美元。此交易代表其持股比例減少了 1.33%。該出售在與 SEC 的法律文件中披露，可以通過此鏈接訪問。目前，16.36% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>多家機構投資者最近買入和賣出了 OLMA 股票。Ameritas Investment Partners Inc.在第二季度將其在 Olema Pharmaceuticals 的持股增加了 55.4%。Ameritas Investment Partners Inc.現在擁有 6,080 股公司股票，價值 26,000 美元，此前在上個季度購買了 2,168 股。Farther Finance Advisors LLC 在第二季度將其在 Olema Pharmaceuticals 的持股增加了 602.9%。Farther Finance Advisors LLC 現在擁有 6,839 股公司股票，價值 29,000 美元，此前在上個季度購買了 5,866 股。FNY Investment Advisers LLC 在第二季度將其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 現在擁有 10,000 股公司股票，價值 42,000 美元，此前在上個季度購買了 5,000 股。Quarry LP 在第一季度購買了 Olema Pharmaceuticals 的新股份，價值約為 45,000 美元。最後，Alpine Global Management LLC 在第一季度購買了 Olema Pharmaceuticals 的新職位，價值約為 52,000 美元。機構投資者持有該公司 91.78% 的股票。</p>
<h2>Olema Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症治療的發現、開發和商業化。其主要產品候選藥物為 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；以及 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行的針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的 1/2 期臨牀試驗，同時開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Olema Pharmaceuticals</li>
<li>如何投資小型股</li>
<li>ServiceNow 的 70 億美元賭注：恐慌還是機會？</li>
<li>現在購買的 3 只沃倫·巴菲特股票</li>
<li>戴爾和惠普正在漲價——投資者應注意</li>
<li>WallStreetBets 是什麼，它們正在關注哪些股票？</li>
<li>為什麼 DLocal 是 2026 年值得關注的頂級新興市場金融科技股票</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
<p>在你考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Olema Pharmaceuticals 並不在名單上。</p>
<p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OLMA

<p>Olema Pharmaceuticals（納斯達克代碼：OLMA）達到了新的 52 周高點，交易價格為 36.13 美元，成交量為 3,355,702 股。分析師們給出了混合評級，普遍共識為 “適度買入”，目標價格為 40.50 美元。該公司報告了第三季度每股虧損 0.49 美元。內部人士活動包括董事 Cyrus Harmon 的出售。機構投資者持有 91.78% 的股份。Olema 專注於女性癌症的治療，其主要產品 OP-1250 正在進行第三階段臨牀試驗</p>

<p>Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $36.13 and last traded at $35.83, with a volume of 3355702 shares traded. The stock had previously closed at $33.05.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 獲取免費報告) 的股價在週二的午盤交易中達到了新的 52 周高點。該股最高交易價格為 36.13 美元，最後交易價格為 35.83 美元，成交量為 3,355,702 股。該股此前收盤價為 33.05 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of equities research analysts have recently commented on OLMA shares. UBS Group reaffirmed a &#34;buy&#34; rating on shares of Olema Pharmaceuticals in a research note on Monday, October 20th. The Goldman Sachs Group boosted their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. HC Wainwright increased their price target on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, December 11th. Guggenheim initiated coverage on Olema Pharmaceuticals in a research report on Wednesday, October 8th. They issued a &#34;buy&#34; rating and a $20.00 price objective for the company. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $40.50.</p>
<div class="lb-trans"><p>多家股票研究分析師最近對 OLMA 股票發表了評論。瑞銀集團在 10 月 20 日的研究報告中重申了對 Olema Pharmaceuticals 股票的 “買入” 評級。高盛集團將 Olema Pharmaceuticals 的目標價格從 26.00 美元上調至 38.00 美元，並在 12 月 11 日的報告中給予該公司 “買入” 評級。HC Wainwright 將 Olema Pharmaceuticals 的目標價格從 36.00 美元上調至 45.00 美元，並在 12 月 11 日的報告中給予該股 “買入” 評級。古根海姆在 10 月 8 日的研究報告中開始覆蓋 Olema Pharmaceuticals。他們對該公司發佈了 “買入” 評級和 20.00 美元的價格目標。最後，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Olema Pharmaceuticals 股票的 “賣出（d-）” 評級。七位分析師對該股給予了買入評級，一位給予了持有評級，一位對該公司的股票發佈了賣出評級。根據 MarketBeat.com 的數據，該股的共識評級為 “適度買入”，共識目標價格為 40.50 美元。</p>
</div><p><strong>Read Our Latest Report on OLMA</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 OLMA 的最新報告</strong></p>
</div><h2>Olema Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票表現</h2>
</div><p>The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The company's fifty day moving average price is $16.23 and its 200 day moving average price is $9.47. The company has a market cap of $2.46 billion, a PE ratio of -19.16 and a beta of 1.87.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.01，流動比率為 8.03，速動比率為 8.03。該公司的 50 日移動平均價格為 16.23 美元，200 日移動平均價格為 9.47 美元。該公司的市值為 24.6 億美元，市盈率為-19.16，貝塔值為 1.87。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.05). On average, equities research analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals (NASDAQ:OLMA - 獲取免費報告) 最近在 11 月 10 日發佈了季度財報。該公司報告每股收益（EPS）為-0.49 美元，低於分析師的共識預期-0.44 美元，差距為 0.05 美元。平均而言，股票研究分析師預測 Olema Pharmaceuticals, Inc.在本年度將發佈-2.33 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In related news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $8.33, for a total transaction of $83,300.00. Following the completion of the sale, the director directly owned 744,140 shares of the company's stock, valued at approximately $6,198,686.20. This trade represents a 1.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 16.36% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Cyrus Harmon 在 9 月 18 日的交易中出售了 10,000 股該股票。該股票以平均價格 8.33 美元出售，總交易額為 83,300.00 美元。出售完成後，該董事直接持有 744,140 股公司股票，估值約為 6,198,686.20 美元。此交易代表其持股比例減少了 1.33%。該出售在與 SEC 的法律文件中披露，可以通過此鏈接訪問。目前，16.36% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors have recently bought and sold shares of OLMA. Ameritas Investment Partners Inc. increased its position in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company's stock valued at $26,000 after purchasing an additional 2,168 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company's stock worth $29,000 after buying an additional 5,866 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock worth $42,000 after buying an additional 5,000 shares during the last quarter. Quarry LP bought a new stake in Olema Pharmaceuticals in the first quarter worth about $45,000. Finally, Alpine Global Management LLC purchased a new position in Olema Pharmaceuticals in the first quarter valued at about $52,000. Institutional investors own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>多家機構投資者最近買入和賣出了 OLMA 股票。Ameritas Investment Partners Inc.在第二季度將其在 Olema Pharmaceuticals 的持股增加了 55.4%。Ameritas Investment Partners Inc.現在擁有 6,080 股公司股票，價值 26,000 美元，此前在上個季度購買了 2,168 股。Farther Finance Advisors LLC 在第二季度將其在 Olema Pharmaceuticals 的持股增加了 602.9%。Farther Finance Advisors LLC 現在擁有 6,839 股公司股票，價值 29,000 美元，此前在上個季度購買了 5,866 股。FNY Investment Advisers LLC 在第二季度將其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 現在擁有 10,000 股公司股票，價值 42,000 美元，此前在上個季度購買了 5,000 股。Quarry LP 在第一季度購買了 Olema Pharmaceuticals 的新股份，價值約為 45,000 美元。最後，Alpine Global Management LLC 在第一季度購買了 Olema Pharmaceuticals 的新職位，價值約為 52,000 美元。機構投資者持有該公司 91.78% 的股票。</p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症治療的發現、開發和商業化。其主要產品候選藥物為 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；以及 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行的針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的 1/2 期臨牀試驗，同時開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>How to Invest in Small Cap Stocks</li>
<li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Dell and HP Are Raising Prices—And Investors Should Take Note</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Olema Pharmaceuticals</li>
<li>如何投資小型股</li>
<li>ServiceNow 的 70 億美元賭注：恐慌還是機會？</li>
<li>現在購買的 3 只沃倫·巴菲特股票</li>
<li>戴爾和惠普正在漲價——投資者應注意</li>
<li>WallStreetBets 是什麼，它們正在關注哪些股票？</li>
<li>為什麼 DLocal 是 2026 年值得關注的頂級新興市場金融科技股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Olema Pharmaceuticals 並不在名單上。</p>
</div><p>While Olema Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Olema Pharmaceuticals（NASDAQ:OLMA）創下 12 個月新高 - 現在是買入的好時機嗎？